0000950170-24-076871.txt : 20240624 0000950170-24-076871.hdr.sgml : 20240624 20240624170802 ACCESSION NUMBER: 0000950170-24-076871 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240621 FILED AS OF DATE: 20240624 DATE AS OF CHANGE: 20240624 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hassard James CENTRAL INDEX KEY: 0001799357 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38583 FILM NUMBER: 241065220 MAIL ADDRESS: STREET 1: 177 E COLORADO BLVD STREET 2: STE 700 CITY: PASADENA STATE: CA ZIP: 91105 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Crinetics Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001658247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 263744114 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-450-6464 MAIL ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 ownership.xml 4 X0508 4 2024-06-21 false 0001658247 Crinetics Pharmaceuticals, Inc. CRNX 0001799357 Hassard James C/O CRINETICS PHARMACEUTICALS, INC. 6055 LUSK BOULEVARD SAN DIEGO CA 92121 false true false false Chief Commercial Officer true Common Stock 2024-06-21 4 M false 15000 19.73 A 44259 D Common Stock 2024-06-21 4 S false 15000 44.66 D 29259 D Stock option (Right to Buy) 19.73 2024-06-21 4 M false 15000 0 D 2032-03-10 Common Stock 15000 145000 D The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $44.66 per share. The range of sales prices on the transaction date was $43.96 to $45.11 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. The option is exercisable as follows: 25% of the shares subject to the option vest on February 28, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Marc Wilson, as attorney-in-fact 2024-06-24